Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.UMRX · Entity 3793 | Director | July 01, 2020 | July 06, 2020 |
| HOOKIPA Pharma Inc.HOOK · Entity 15295 | Director · Chief Executive Officer | April 15, 2024 | April 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date July 01, 2020 · Filed July 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.47 · Expires 2030-07-01 | Direct | 40,090 |
Reported balance
After 2020-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-01 · Grant · Acquired 40,090 · Balance 40,090 F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2: This option is fully vested at time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
F2: This option is fully vested at time of grant.
HOOKIPA Pharma Inc.
Report date April 15, 2024 · Filed April 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.76 · Expires 2034-04-15 | Direct | 971,400 |
Reported balance
After 2024-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-15 · Grant · Acquired 971,400 · Balance 971,400 F1: 25% of this option shall vest on April 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest on April 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2024 Filed Apr 17, 2024 16:15 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 971,400 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001415889-24-010960 · form4-04172024_040403.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 971,400 Underlying: Common Stock · 971,400 shares Expires 2034-04-15 F1 · derivative.exercise_date: 25% of this option shall vest on April 15, 2025, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| July 11, 2023 Filed Jul 11, 2023 18:21 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | PurchaseCommon Stock | 5,000 | $0.83 | $4,142.00 |
DisclosureSEC source: 0001104659-23-080056 · tm2321093-1_4seq1.xml · nonDerivative · entry 2 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,952 Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 18:21 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | PurchaseCommon Stock | 5,000 | $0.81 | $4,050.00 |
DisclosureSEC source: 0001104659-23-080056 · tm2321093-1_4seq1.xml · nonDerivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,952 Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 17:06 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | PurchaseCommon Stock | 5,000 | $0.89 | $4,450.00 |
DisclosureSEC source: 0001104659-23-079179 · tm2320881-1_4seq1.xml · nonDerivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,952 Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 19:37 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | PurchaseCommon Stock | 5,000 | $0.89 | $4,455.50 |
DisclosureSEC source: 0001104659-23-078332 · tm2320620-1_4seq1.xml · nonDerivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,952 Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 19:46 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 513,600 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-23-046887 · tm2312963-4_4seq1.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,600 Underlying: Common Stock · 513,600 shares Expires 2033-04-14 F1 · derivative.exercise_date: 25% of this option shall vest on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 16:05 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 275,250 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001104659-22-076811 · tm2220275-1_4seq1.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,250 Underlying: Common Stock · 275,250 shares Expires 2032-04-19 F1 · derivative.exercise_date: 25% of this option shall vest on April 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| April 19, 2022 Filed Apr 20, 2022 16:24 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 275,250 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001104659-22-047844 · tm2213143-2_4seq1.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,250 Underlying: Common Stock · 275,250 shares Expires 2032-04-19 F1 · derivative.exercise_date: 25% of this option shall vest on April 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| February 01, 2022 Filed Feb 1, 2022 20:44 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 39,853 | $3.00 Strike: $1.50 | $119,559.00 |
DisclosureSEC source: 0001104659-22-010534 · tm225144-1_4seq1.xml · derivative · entry 2 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,853 Underlying: Common Stock · 39,853 shares Expires 2032-01-31 F2 · derivative.exercise_date: This stock option is fully vested. Read SEC document |
| February 01, 2022 Filed Feb 1, 2022 20:44 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantCommon Stock | 47,824 | $3.00 | $143,472.00 |
DisclosureSEC source: 0001104659-22-010534 · tm225144-1_4seq1.xml · nonDerivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,952 F1 · shares: The Reporting Person was awarded 47,824 unrestricted shares of common stock as a portion of their base salary for the six month ending June 30, 2022. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:31 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 207,600 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001104659-21-053187 · tm2113596-2_4seq1.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,600 Underlying: Common Stock · 207,600 shares Expires 2031-04-19 F1 · derivative.exercise_date: 25% of this option shall vest on April 19, 2022, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 16:01 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantCommon Stock | 4,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-085605 · a4.xml · nonDerivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,128 F1 · shares: The Reporting Person was awarded 4,128 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of HOOKIPA Pharma Inc.'s Common Stock. The restricted stock units vest shall vest in four equal installments on March 20, 2021, May 15, 2021, August 15, 2021 and November 15, 2021. The restricted stock units may be settled only by delivering shares of HOOKIPA Pharma Inc.'s Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:15 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 40,090 | $0.31 Strike: $0.47 | $12,500.06 |
DisclosureSEC source: 0001209191-20-041003 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,090 Underlying: Common Stock · 40,090 shares Expires 2030-07-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 20:22 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 14,331 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-20-035923 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,331 Underlying: Common Stock · 14,331 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 20, 2020 Filed Apr 24, 2020 08:54 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001104659-20-050691 · a4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2030-04-20 F1 · derivative.exercise_date: 25% of this option shall vest on February 15, 2021, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 21:40 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 56,690 | $0.22 Strike: $0.35 | $12,500.15 |
DisclosureSEC source: 0001209191-20-023943 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,690 Underlying: Common Stock · 56,690 shares Expires 2030-04-06 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:45 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 29,790 | $0.45 Strike: $0.72 | $13,500.83 |
DisclosureSEC source: 0001209191-20-001888 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,790 Underlying: Common Stock · 29,790 shares Expires 2030-01-02 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:37 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 15,352 | $0.88 Strike: $1.41 | $13,500.55 |
DisclosureSEC source: 0001209191-19-052238 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,352 Underlying: Common Stock · 15,352 shares Expires 2029-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:04 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 7,608 | $1.77 Strike: $2.41 | $13,500.40 |
DisclosureSEC source: 0001209191-19-041035 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,608 Underlying: Common Stock · 7,608 shares Expires 2029-07-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:13 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 14,331 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-19-038214 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,331 Underlying: Common Stock · 14,331 shares Expires 2029-06-18 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) June 18, 2020, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 17, 2019 Filed Apr 24, 2019 17:33 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 604,656 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-19-023450 · a4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,656 Underlying: Common Stock · 604,656 shares Expires 2029-04-17 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 17, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:17 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 4,966 | $2.72 Strike: $4.40 | $13,500.07 |
DisclosureSEC source: 0001209191-19-023093 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,966 Underlying: Common Stock · 4,966 shares Expires 2029-04-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:50 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 4,999 | $2.70 Strike: $4.47 | $13,497.30 |
DisclosureSEC source: 0001209191-19-002037 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,999 Underlying: Common Stock · 4,999 shares Expires 2029-01-02 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:10 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,171 | $6.22 Strike: $10.37 | $13,503.62 |
DisclosureSEC source: 0001209191-18-053949 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,171 Underlying: Common Stock · 2,171 shares Expires 2028-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| July 26, 2018 Filed Sep 26, 2018 22:37 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,547 | $8.72 Strike: $14.57 | $13,489.84 |
DisclosureSEC source: 0001209191-18-052354 · doc4.xml · derivative · entry 1 Aldag Jorn · CIK 0001734412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,547 Underlying: Common Stock · 1,547 shares Expires 2028-07-26 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.